Finance
Biopharma company announces net loss of $0.10 per share for the year
Published in Cardiovascular Week, April 25th, 2005
The company had a net loss of $3,326,399 or $0.10 per share for the year ended December 31, 2004, compared with net loss of $1,659,875 or $0.06 per share for the year ended December 31, 2003. The net loss for 2004 resulted primarily from the continued research and development expenditures related to the initiation of phase II clinical trials to study the company's product, Thymosin beta 4 (TB4) for the treatment of chronic dermal wounds, research and development efforts related to its technology, scale-up manufacturing and formulation efforts, and the administrative costs...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
Source: Cardiovascular Week (2005-04-25)
More Articles from Cardiovascular Week
- Angiology
Invasive MRI is feasible and apparently safe during peripheral angioplasty - Atherosclerosis
LRP1 plays a pathologic function during atherosclerotic lesion progression - Cardioprotection
Nonerythropoietic derivatives may be more effective for treating CV diseases - Hypertension
Majority of hypertensive patients will require combination therapy - Pulmonary Hypertension
Oxidant stress decreases with epoprostenol therapy - Acute Pulmonary Embolism
L-Arginine attenuates APE-induced pulmonary hypertension in rats - More from this issue of Cardiovascular Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
